Lexeo Therapeutics Appoints New CMO, Director
Ticker: LXEO · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $40,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, personnel
TL;DR
Lexeo Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
Lexeo Therapeutics, Inc. announced on July 8, 2024, the appointment of Dr. Christopher Adams as Chief Medical Officer and the election of Ms. Sarah Kelly to its Board of Directors. The company also disclosed compensatory arrangements for certain officers. These changes are effective immediately.
Why It Matters
Key leadership changes at Lexeo Therapeutics could signal strategic shifts in the company's direction and its approach to developing its therapeutic pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- Dr. Christopher Adams (person) — Appointed Chief Medical Officer
- Ms. Sarah Kelly (person) — Elected to Board of Directors
- July 08, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Christopher Adams has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah Kelly has been elected to the Board of Directors.
What is the effective date of these changes?
The earliest event reported is dated July 08, 2024, indicating these changes are effective on or around this date.
What other information is disclosed in this filing?
The filing also discloses compensatory arrangements of certain officers.
What is Lexeo Therapeutics, Inc.'s state of incorporation?
Lexeo Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-07-08 07:01:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
- $40,000 — cy, Mr. Van Hauwermeiren is entitled to $40,000 in annual cash compensation for service
Filing Documents
- lxeo-20240708.htm (8-K) — 44KB
- lxeo-ex99_1.htm (EX-99.1) — 11KB
- img46940271_0.jpg (GRAPHIC) — 243KB
- 0000950170-24-081942.txt ( ) — 508KB
- lxeo-20240708.xsd (EX-101.SCH) — 25KB
- lxeo-20240708_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On July 8, 2024, the Company issued a press release announcing Mr. Van Hauwermeiren's appointment to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: July 8, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer